Positive Topline Results for SEQUOIA-HCM Trial in OHCM
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.
Source: medscape.com
Stay updated with breaking news from Cardiac Endpoints. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.